Trial Profile
Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Allergan
- 21 Aug 2018 Planned number of patients changed from 12 to 22.
- 14 Aug 2018 New trial record